Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Sohm Inc (OP: SHMN )

0.0011 UNCHANGED
Streaming Delayed Price Updated: 11:46 AM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0011
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0011
Today's Range 0.0011 - 0.0011
52wk Range 0.0006 - 0.0022
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
Via ACCESSWIRE
BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology
Via Investor Brand Network

Performance

YTD
-31.25%
-31.25%
1 Month
+10.00%
+10.00%
3 Month
-21.43%
-21.43%
6 Month
-15.38%
-15.38%
1 Year
+22.22%
+22.22%

More News

Read More
InvestorNewsBreaks – SOHM, Inc. (SHMN), Coastar Therapeutics Collaborate to Advance Field of Genome Editing
Via Investor Brand Network
Rheumatoid Arthritis Patients Face Heightened Risk of Depression, Study Finds
Via Investor Brand Network
Why Prescription Drugs Can Be Costly
Via Investor Brand Network
SOHM Inc. (SHMN) Is ‘One to Watch’
Via Investor Brand Network
FDA Grants Florida Permission to Import More Affordable Medicines from Canada
Via Investor Brand Network
Exposures Product Safety
Small Study Shows Existing Drug Could Reduce Opioid Administration After Surgery
Via Investor Brand Network
New Compound Promises Greater Efficacy Against Pain, Has No Side Effects
Via Investor Brand Network
BioMedNewsBreaks– SOHM Inc. (SHMN) Announces Filing of Provisional Patent for ABBIE Smart Gene Editing Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
From SOHM, Inc.
Via GlobeNewswire
FDA Announces Changes to Safety Labeling Requirements for Opioid Medications
Via Investor Brand Network
Exposures Product Safety
SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California
Via Investor Brand Network
BioMedNewsBreaks — Why SOHM Inc. (SHMN) Is ‘One to Watch’
Via Investor Brand Network
Senate Committee Hears How Drug Shortages Impact Patients
Via Investor Brand Network
SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems
Via Investor Brand Network
SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement
Via Investor Brand Network
BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces 2024 Outlook for Business Units
Via Investor Brand Network
SOHM Announces Business Outlook for 2024
From SOHM, Inc.
Via GlobeNewswire
Topical Analgesics Emerge as Important Pain-Management Tools
Via Investor Brand Network
BioMedNewsBreaks – SOHM, Inc. (SHMN) Launches Carlsbad-Based CDMO GMP Manufacturing Facility
Via Investor Brand Network
SOHM Announces New CDMO GMP Manufacturing Facility in Carlsbad, California
From SOHM, Inc.
Via GlobeNewswire
Study Shows Patients Afflicted by Inflammatory Arthritis Face Numerous Mental Challenges at Work
Via Investor Brand Network
BioMedNewsBreaks – SOHM Inc. (SHMN) Unveils New Suite of SOHM Nutrients’ Brand Chewables
Via Investor Brand Network
SOHM OTC Self-care Launches Suite of 13 New SOHM Nutrients’ Brand Chewables
From SOHM, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.